End-of-day quote
Shenzhen S.E.
23:00:00 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
8.55
CNY
|
+2.64%
|
|
+14.92%
|
-8.75%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,608
|
2,063
|
2,747
|
3,739
|
4,503
|
3,111
|
Enterprise Value (EV)
1 |
1,662
|
2,301
|
3,074
|
4,103
|
4,807
|
3,479
|
P/E ratio
|
26.8
x
|
25.5
x
|
26.5
x
|
32.6
x
|
27.8
x
|
19.5
x
|
Yield
|
1.94%
|
-
|
-
|
0.83%
|
0.74%
|
-
|
Capitalization / Revenue
|
0.53
x
|
0.64
x
|
0.83
x
|
1.07
x
|
1.12
x
|
0.73
x
|
EV / Revenue
|
0.55
x
|
0.71
x
|
0.93
x
|
1.17
x
|
1.2
x
|
0.81
x
|
EV / EBITDA
|
9.37
x
|
12.7
x
|
15.9
x
|
18.5
x
|
18.2
x
|
10.1
x
|
EV / FCF
|
5.99
x
|
15.6
x
|
-16.3
x
|
-157
x
|
10.7
x
|
-46.1
x
|
FCF Yield
|
16.7%
|
6.41%
|
-6.13%
|
-0.64%
|
9.37%
|
-2.17%
|
Price to Book
|
1.27
x
|
1.56
x
|
1.94
x
|
2.45
x
|
2.61
x
|
1.65
x
|
Nbr of stocks (in thousands)
|
312,141
|
312,141
|
312,141
|
312,141
|
332,111
|
332,026
|
Reference price
2 |
5.150
|
6.610
|
8.800
|
11.98
|
13.56
|
9.370
|
Announcement Date
|
25/04/19
|
23/04/20
|
22/04/21
|
28/04/22
|
19/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
3,013
|
3,238
|
3,321
|
3,502
|
4,004
|
4,275
|
EBITDA
1 |
177.4
|
180.6
|
193
|
221.9
|
263.5
|
343
|
EBIT
1 |
102.9
|
110.4
|
122.7
|
145.6
|
170.5
|
242.1
|
Operating Margin
|
3.41%
|
3.41%
|
3.69%
|
4.16%
|
4.26%
|
5.66%
|
Earnings before Tax (EBT)
1 |
93.09
|
119.9
|
138.1
|
149.7
|
202.3
|
214.9
|
Net income
1 |
60.93
|
80.92
|
103.7
|
114.6
|
154.4
|
159.3
|
Net margin
|
2.02%
|
2.5%
|
3.12%
|
3.27%
|
3.86%
|
3.73%
|
EPS
2 |
0.1921
|
0.2589
|
0.3323
|
0.3671
|
0.4869
|
0.4796
|
Free Cash Flow
1 |
277.6
|
147.4
|
-188.4
|
-26.15
|
450.6
|
-75.51
|
FCF margin
|
9.21%
|
4.55%
|
-5.67%
|
-0.75%
|
11.25%
|
-1.77%
|
FCF Conversion (EBITDA)
|
156.44%
|
81.65%
|
-
|
-
|
171.01%
|
-
|
FCF Conversion (Net income)
|
455.56%
|
182.18%
|
-
|
-
|
291.8%
|
-
|
Dividend per Share
2 |
0.1000
|
-
|
-
|
0.1000
|
0.1000
|
-
|
Announcement Date
|
25/04/19
|
23/04/20
|
22/04/21
|
28/04/22
|
19/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
54.6
|
237
|
327
|
364
|
304
|
368
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.3078
x
|
1.314
x
|
1.696
x
|
1.639
x
|
1.152
x
|
1.073
x
|
Free Cash Flow
1 |
278
|
147
|
-188
|
-26.1
|
451
|
-75.5
|
ROE (net income / shareholders' equity)
|
4.83%
|
6.16%
|
7.36%
|
7.28%
|
8.56%
|
8.56%
|
ROA (Net income/ Total Assets)
|
2.23%
|
2.1%
|
2.13%
|
2.44%
|
2.5%
|
3.42%
|
Assets
1 |
2,736
|
3,852
|
4,866
|
4,694
|
6,181
|
4,664
|
Book Value Per Share
2 |
4.060
|
4.240
|
4.530
|
4.900
|
5.200
|
5.690
|
Cash Flow per Share
2 |
0.9600
|
1.120
|
0.8800
|
0.8100
|
1.060
|
0.9600
|
Capex
1 |
84.6
|
146
|
191
|
157
|
81.8
|
152
|
Capex / Sales
|
2.81%
|
4.5%
|
5.74%
|
4.49%
|
2.04%
|
3.56%
|
Announcement Date
|
25/04/19
|
23/04/20
|
22/04/21
|
28/04/22
|
19/04/23
|
25/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -8.75% | 392M | | +33.25% | 699B | | +28.59% | 571B | | -3.55% | 364B | | +18.16% | 326B | | +4.36% | 286B | | +14.81% | 236B | | +4.93% | 198B | | -9.78% | 194B | | -3.69% | 149B |
Other Pharmaceuticals
|